Glucorticosteroids topical

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 03.01.2023

Dieser Artikel auf Deutsch

Synonym(s)

Corticosteroids; Cortisone allergy; Glucocorticoidexterna; Glucocorticoid Externum; Glucocorticoids topical; Glucocorticoids, topical; Glucorticosteroids topical; Topical corticosteroids; topical steroids; Topical steroids

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Glucocorticoids for topical application.

ClassificationThis section has been translated automatically.

Overview of topical glucocorticoids (monopreparations, modified classification according to Niedner)

Class I (mild)

  • dexamethasone (0.02-0.05%)
  • clobetasone butyrate (0.05%)
  • hydrocortisone (0.25%-1.0%)
  • Hydrocortisone acetate (0.25-1.0%)
  • Prednisolone (0.4-0.5%)

Class II (moderately strong)

  • Alclometasone dipropionate (0.05%)
  • Betamethasone valerate(0.05%)
  • Desoximetasone (0.25%)
  • Flumethasone (0.02%)
  • Flumetasone-pivalate (0.02%)
  • Fluocortolone (0.25%)
  • Flupredniden-21-acetat (0,1-2,5%)
  • Hydrocortisone-17-butyrate (0.1%)
  • hydrocortisone acetate (0.1%)
  • hydrocortisone buteprate (0.1%)
  • methylprednisolone aceponate (0.1%)
  • prednicarbate (0.25%)
  • Triamcinolone acetonide (0.05-0.1%)
  • dexamethasone (0.1%)

Class III (strong)

  • Amcinonide (0.1%)
  • Betamethasone-17,21-dipropionate (0.05%)
  • Betamethasone-17-valerate (0.1%)
  • Desoximetasone (0.05%)
  • diflorasone-diacetate (0.01%)
  • diflucortolone-21-pentanoate (0.1%)
  • Fluocinolone acetonide (0.025- 0.1%)
  • Fluticasone propionate (0.025-0.1%)
  • Mometasone furoate (0.1%)

Class IV (very strong)

  • Clobetasol-propionate (0.05%)
  • Diflucortolon-valerate (0.3%)

IndicationThis section has been translated automatically.

Inflammatory dermatoses, especially eczema diseases and localized forms of psoriasis vulgaris.

Limited indicationThis section has been translated automatically.

Pregnancy, first trimester, nursing, diaper rash.

Dosage and method of useThis section has been translated automatically.

Depending on the concentration of the topical glucocorticoid and the indication, apply thinly 1-3 times/day to the affected skin areas.

On palms and soles, application under hourly (2-4h) occlusion is recommended.

Intermittent maintenance therapy prolongs remission times.

Undesirable effectsThis section has been translated automatically.

Allergic reactions, glaucoma with prolonged use in the eye area, purpura, Cushing's syndrome, acne, infections, perioral dermatitis, folliculitis, skin atrophy, striae cutis distensae, skin dryness, hypertrichosis, wound healing disorders.

Contact allergic reactions are observed (Wurpts G 2018). Their incidence is (astonishing!) 0.2-5.0% according to an older European study. 85% of these patients are sensitized to more than one glucocorticoid (Wurpts G 2018).

Topical glucocortioids are divided into 4 groups according to allergological relevance (see also glucocorticoids epicutaneous test series):

  • A (hydrocortisone type)
  • B (acetonide type)
  • C (Betamethasone type)
  • D (ester type - esterifications in the C16 position).

Halogenation in C6 position reduces the risk of sensitization. Moderate sensitization accumulations are found with amcinonide, hydrocortisone-17-butyrate and budesonide.


InteractionsThis section has been translated automatically.

With simultaneous application of idoxuridine delay of wound healing.

ContraindicationThis section has been translated automatically.

Perioral dermatitis, bacterial skin inflammations (monotherapy), skin tuberculosis, vaccination reactions, syphilis, mycoses, rosacea, varicella.

Note(s)This section has been translated automatically.

Application in the facial area should only be carried out under strict indication.

In the case of large-area application, a not inconsiderable systemic resorption must be expected, especially in inflammatory dermatoses.

Important for histological clarification of inflammatory dermatoses: in order to obtain relevant information, external glucocorticoids must be discontinued for several days (7-10 days) beforehand, as an assessment is otherwise not very meaningful.

Various topical glucocorticoids can be combined with topical antibiotics or topical antiseptics (see below Glucocorticoids topical, combinations).

LiteratureThis section has been translated automatically.

  1. Castela E et al (2012) Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol 26: Suppl 3, 47-51
  2. Dooms-Goossens A et al (1996) Corticosteroid contact allergy: an EECDRG multicentre study. Contact dermatitis 35:40-44.
  3. Goossens A (2000) Reactions to corticosteroids: some new aspects regarding cross-sensitivity. Cutis 65:43-45.
  4. Wurtps G (2018) Contact allergy to glucocorticoids. Allergo J 27: 13-15

Authors

Last updated on: 03.01.2023

Author: Prof. Dr. med. Peter Altmeyer

Editors: Susanne NeumannDr. med. Silke Tremper